Menu
Search
|

Menu

Close
X

Mersana Therapeutics Inc MRSN.OQ (NASDAQ Stock Exchange Global Select Market)

8.02 USD
-0.29 (-3.49%)
As of Oct 19
chart
Previous Close 8.31
Open 8.34
Volume 15,166
3m Avg Volume 50,446
Today’s High 8.71
Today’s Low 8.01
52 Week High 23.67
52 Week Low 7.79
Shares Outstanding (mil) 22.71
Market Capitalization (mil) 429.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
18
FY16
25
EPS (USD)
FY18
-1.082
FY17
-1.702
FY16
-0.605
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.83
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
12.76
Return on Investment (TTM)
vs sector
--
14.27
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

David Mott
Independent Chairman of the Board, Since 2017
Salary: --
Bonus: --
Anna Protopapas
President, Chief Executive Officer, Director, Since 2016
Salary: $430,148.00
Bonus: --
David Spellman
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Michael Kaufman
Senior Vice President - Chemistry, Manufacturing and Controls, Since 2016
Salary: --
Bonus: --
Timothy Lowinger
Chief Scientific Officer, Since
Salary: $370,162.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

840 Memorial Dr
CAMBRIDGE   MA   02139-3789

Phone: +1617.4980020

Mersana Therapeutics, Inc. is a biotechnology company. The Company is focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies.

SPONSORED STORIES